康乐卫士三价HPV疫苗通过注册现场核查

Core Viewpoint - 康乐卫士 has made significant progress in the application for the market approval of its trivalent HPV vaccine following the successful completion of the on-site inspection by the National Medical Products Administration [1] Group 1 - 康乐卫士 and its subsidiary, 康乐卫士 (昆明) 生物技术有限公司, received a notification from the National Medical Products Administration on July 23 regarding the on-site inspection for drug registration [1] - The company has recently passed the on-site inspection for its trivalent HPV vaccine, which is based on E. coli [1] - The successful completion of the registration inspection lays a solid foundation for the approval of the trivalent HPV vaccine for market launch [1]